San Diego-centered Viking Therapeutics marked by itself as a significant competitor within the weight loss drug market in February immediately after revealing promising info from a mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as in